Advertisement
UK markets close in 6 hours 12 minutes

  • FTSE 100

    8,081.04
    +36.23 (+0.45%)
     

  • FTSE 250

    19,789.27
    -10.45 (-0.05%)
     

  • AIM

    754.86
    -0.01 (-0.00%)
     

  • GBP/EUR

    1.1633
    +0.0005 (+0.04%)
     

  • GBP/USD

    1.2435
    -0.0018 (-0.14%)
     

  • Bitcoin GBP

    53,407.40
    +95.75 (+0.18%)
     

  • CMC Crypto 200

    1,434.31
    +10.21 (+0.72%)
     

  • S&P 500

    5,070.55
    +59.95 (+1.20%)
     

  • DOW

    38,503.69
    +263.71 (+0.69%)
     

  • CRUDE OIL

    83.06
    -0.30 (-0.36%)
     

  • GOLD FUTURES

    2,331.40
    -10.70 (-0.46%)
     

  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     

  • HANG SENG

    17,201.27
    +372.34 (+2.21%)
     

  • DAX

    18,182.79
    +45.14 (+0.25%)
     

  • CAC 40

    8,122.00
    +16.22 (+0.20%)
     
Money:

The five essential pieces of financial paperwork you must never lose

Mislaying key documents can cause real headaches, so it’s worth tracking down these most commonly-lost bits of paperwork

Pharvaris to Participate in Upcoming September Investor Conferences

Pharvaris N.V.
·2-min read

ZUG, Switzerland, Sept. 03, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin-B2-receptor-mediated indications, today announced that management will participate in the following three upcoming investor conferences in September:

Morgan Stanley 19th Annual Global Healthcare Conference
Format: Live Fireside Chat
Date/Time: Friday, September 10, 2021 at 5:00 PM CEST (11:00 a.m. EDT)

H.C. Wainwright 23rd Annual Global Investment Conference
Format: On Demand Presentation
Date/Time: Monday, September 13, 2021 at 1:00 PM CEST (7:00 a.m. EDT)

Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
Format: Live Presentation
Date/Time: Tuesday, September 21, 2021 at 3:05 PM CEST (9:05 a.m. EDT)

ADVERTISEMENT

Live audio webcasts of these presentations will be available on the Investors section of the Pharvaris website at: https://ir.pharvaris.com/news-events/events-presentations. A replay will be available on Pharvaris’ website for 30 days after each respective date.

About Pharvaris
Pharvaris is a clinical-stage company focused on bringing oral bradykinin-B2-receptor antagonists to patients. By targeting this clinically proven therapeutic target with novel small molecules, the Pharvaris team is advancing new alternatives to injected therapies for all sub-types of HAE and other bradykinin-mediated diseases. The Company brings together executives with a breadth of expertise across pharmaceutical development and rare disorders, including HAE. For more information, visit https://pharvaris.com/.

For more information:
Pharvaris
Maryann Cimino
Director of Corporate Relations
+1-617-710-7305
maryann.cimino@pharvaris.com

Investor Contact
Sarah McCabe
Stern Investor Relations, Inc.
+1-212-362-1200
sarah.mccabe@sternir.com

Media Contact
Maggie Beller
Russo Partners, LLC
+1-646-942-5631
maggie.beller@russopartnersllc.com